Biological
individualized anti-tumor new antigen iNeo-Vac-R01 injection
individualized anti-tumor new antigen iNeo-Vac-R01 injection is a biological therapy with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(4)
Detailed Status
Not yet recruiting2
Recruiting2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
not_yet_recruiting250%
recruiting250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_1
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
NCT06995105
recruitingphase_1
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
NCT06956716
not_yet_recruitingphase_1
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
NCT06888674
not_yet_recruitingphase_1
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
NCT06888648
Clinical Trials (4)
Showing 4 of 4 trials
NCT06995105Phase 1
Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma
NCT06956716Phase 1
Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma
NCT06888674Phase 1
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
NCT06888648Phase 1
Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4